| Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer. (NCT02160795) | National Cancer Institute (NCI) | 2014-03-27 |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740) | National Cancer Institute (NCI) | 2014-03-26 |
| Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer (NCT02610439) | National Cancer Institute (NCI) | 2014-03-25 |
| Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer (NCT02610413) | National Cancer Institute (NCI) | 2014-03-25 |
| Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer (NCT02610426) | National Cancer Institute (NCI) | 2014-03-25 |
| Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (NCT01989585) | National Cancer Institute (NCI) | 2014-03-24 |
| Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis (NCT02066181) | National Cancer Institute (NCI) | 2014-03-21 |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02048813) | National Cancer Institute (NCI) | 2014-03-10 |
| Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction (NCT02070549) | National Cancer Institute (NCI) | 2014-03-10 |
| Blood Collection From People With Ovarian Cancer (NCT02063464) | National Cancer Institute (NCI) | 2014-03-10 |
| Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01896999) | National Cancer Institute (NCI) | 2014-03-07 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT02196168) | National Cancer Institute (NCI) | 2014-03-01 |
| A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (NCT02107963) | National Cancer Institute (NCI) | 2014-02-28 |
| Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (NCT02111863) | National Cancer Institute (NCI) | 2014-02-21 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (NCT02003209) | National Cancer Institute (NCI) | 2014-02-18 |
| Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer (NCT02059265) | National Cancer Institute (NCI) | 2014-02-14 |
| Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity (NCT00067821) | National Cancer Institute (NCI) | 2014-02-11 |
| A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya (NCT00901173) | National Cancer Institute (NCI) | 2014-02-10 |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (NCT02111850) | National Cancer Institute (NCI) | 2014-02-07 |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations (NCT01989546) | National Cancer Institute (NCI) | 2014-02-04 |
| Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (NCT02042443) | National Cancer Institute (NCI) | 2014-02-01 |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma (NCT02062359) | National Cancer Institute (NCI) | 2014-02-01 |
| Study of Variation Over Time in the Oral Microbiome (NCT02049398) | National Cancer Institute (NCI) | 2014-01-28 |
| Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome (NCT02052908) | National Cancer Institute (NCI) | 2014-01-27 |
| A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome (NCT01981525) | National Cancer Institute (NCI) | 2014-01-27 |
| Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01950390) | National Cancer Institute (NCI) | 2014-01-24 |
| A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer (NCT02019693) | National Cancer Institute (NCI) | 2014-01-24 |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (NCT01886872) | National Cancer Institute (NCI) | 2014-01-15 |
| MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (NCT01827384) | National Cancer Institute (NCI) | 2014-01-07 |
| Rapid Autopsy and Procurement of Cancer Tissue (NCT01851395) | National Cancer Institute (NCI) | 2013-12-30 |
| Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (NCT02015104) | National Cancer Institute (NCI) | 2013-12-18 |
| Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02029950) | National Cancer Institute (NCI) | 2013-12-16 |
| Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors (NCT02015065) | National Cancer Institute (NCI) | 2013-12-14 |
| Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma (NCT02015026) | National Cancer Institute (NCI) | 2013-12-13 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (NCT01993719) | National Cancer Institute (NCI) | 2013-12-12 |
| Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism (NCT02001051) | National Cancer Institute (NCI) | 2013-11-27 |
| Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma (NCT01979523) | National Cancer Institute (NCI) | 2013-11-21 |
| Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan (NCT02017288) | National Cancer Institute (NCI) | 2013-11-18 |
| Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (NCT01979536) | National Cancer Institute (NCI) | 2013-11-13 |
| Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy (NCT01834001) | National Cancer Institute (NCI) | 2013-11-13 |
| Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer (NCT01822496) | National Cancer Institute (NCI) | 2013-11-04 |
| Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis (NCT01981551) | National Cancer Institute (NCI) | 2013-10-31 |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01989598) | National Cancer Institute (NCI) | 2013-10-30 |
| Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT01912625) | National Cancer Institute (NCI) | 2013-10-28 |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer (NCT01967823) | National Cancer Institute (NCI) | 2013-10-24 |
| Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma (NCT01849146) | National Cancer Institute (NCI) | 2013-10-24 |
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma (NCT01967576) | National Cancer Institute (NCI) | 2013-10-19 |
| Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors (NCT01967537) | National Cancer Institute (NCI) | 2013-10-18 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (NCT01902173) | National Cancer Institute (NCI) | 2013-10-08 |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01964924) | National Cancer Institute (NCI) | 2013-10-02 |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (NCT01907815) | National Cancer Institute (NCI) | 2013-10-01 |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01935973) | National Cancer Institute (NCI) | 2013-09-30 |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery (NCT01947023) | National Cancer Institute (NCI) | 2013-09-27 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01955499) | National Cancer Institute (NCI) | 2013-09-24 |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (NCT01841736) | National Cancer Institute (NCI) | 2013-09-20 |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma (NCT01950572) | National Cancer Institute (NCI) | 2013-09-09 |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (NCT01922076) | National Cancer Institute (NCI) | 2013-09-03 |
| Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01902160) | National Cancer Institute (NCI) | 2013-09-01 |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (NCT01940809) | National Cancer Institute (NCI) | 2013-08-28 |
| Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (NCT01856192) | National Cancer Institute (NCI) | 2013-08-27 |
| Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction (NCT01907802) | National Cancer Institute (NCI) | 2013-08-23 |
| Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer (NCT01867333) | National Cancer Institute (NCI) | 2013-08-12 |
| Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers (NCT01935960) | National Cancer Institute (NCI) | 2013-08-01 |
| Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery (NCT01835145) | National Cancer Institute (NCI) | 2013-07-31 |
| Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (NCT01861106) | National Cancer Institute (NCI) | 2013-07-24 |
| Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer (NCT01875250) | National Cancer Institute (NCI) | 2013-07-22 |
| Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer (NCT01915225) | National Cancer Institute (NCI) | 2013-07-21 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012) | National Cancer Institute (NCI) | 2013-07-17 |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (NCT01851369) | National Cancer Institute (NCI) | 2013-07-12 |
| Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (NCT01913691) | National Cancer Institute (NCI) | 2013-07-09 |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer (NCT01835158) | National Cancer Institute (NCI) | 2013-07-08 |
| Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (NCT01861314) | National Cancer Institute (NCI) | 2013-07-03 |
| Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (NCT01829568) | National Cancer Institute (NCI) | 2013-06-26 |
| Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus (NCT01822522) | National Cancer Institute (NCI) | 2013-06-21 |
| Antibody Treatment for Advanced Celiac Disease (NCT01893775) | National Cancer Institute (NCI) | 2013-06-12 |
| Breast Tissue Study of Breast Diseases Among Women in Hong Kong (NCT01885039) | National Cancer Institute (NCI) | 2013-06-12 |
| Evaluation of National Cancer Institute Young Adult Stop-Smoking Program (NCT01885052) | National Cancer Institute (NCI) | 2013-06-12 |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (NCT01875601) | National Cancer Institute (NCI) | 2013-06-11 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery (NCT01886573) | National Cancer Institute (NCI) | 2013-06-01 |
| Cigarette Smoking and Oral Microbiota (NCT01862809) | National Cancer Institute (NCI) | 2013-05-23 |
| Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NCT01866410) | National Cancer Institute (NCI) | 2013-05-20 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (NCT01822509) | National Cancer Institute (NCI) | 2013-05-16 |
| Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research (NCT01851382) | National Cancer Institute (NCI) | 2013-05-15 |
| Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer (NCT01867424) | National Cancer Institute (NCI) | 2013-05-14 |
| Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT01935934) | National Cancer Institute (NCI) | 2013-05-08 |
| Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (NCT01811212) | National Cancer Institute (NCI) | 2013-05-08 |
| Tremelimumab With Chemoembolization or Ablation for Liver Cancer (NCT01853618) | National Cancer Institute (NCI) | 2013-05-02 |
| Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors (NCT01849250) | National Cancer Institute (NCI) | 2013-05-01 |
| Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer (NCT01935947) | National Cancer Institute (NCI) | 2013-05-01 |
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (NCT01870596) | National Cancer Institute (NCI) | 2013-05-01 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery (NCT01835184) | National Cancer Institute (NCI) | 2013-05-01 |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (NCT01841723) | National Cancer Institute (NCI) | 2013-04-30 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01886859) | National Cancer Institute (NCI) | 2013-04-26 |
| Surgery and Heated Chemotherapy for Adrenocortical Carcinoma (NCT01833832) | National Cancer Institute (NCI) | 2013-04-12 |
| Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (NCT01935921) | National Cancer Institute (NCI) | 2013-04-09 |
| Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma (NCT01849263) | National Cancer Institute (NCI) | 2013-04-02 |
| Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer (NCT01856322) | National Cancer Institute (NCI) | 2013-04-01 |
| Study of Lung Health Among Workers Exposed to Diesel Exhaust (NCT01867450) | National Cancer Institute (NCI) | 2013-03-28 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01708941) | National Cancer Institute (NCI) | 2013-03-25 |